NEW YORK, Sept. 22 (GenomeWeb News) - Myriad Proteomics said today that it has changed its name to Prolexys Pharmaceuticals to more accurately represent its strategic focus "after making the conversion from a technology-focused organization to a drug discovery company."

Prolexys plans to use information about protein interactions to discover and validate new drug targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.